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Abstract
Cyclin kinase inhibitor p21 is one of the most potent inhibitors of aortic smooth muscle cell
proliferation, a key mediator of atherosclerosis. This study tests if p2l deficiency will result in severe
atherosclerosis in a mouse model. p21-/- and strain matched wild type mice were fed with high fat
diet for 21 weeks. Analysis for biochemical parameters (cholesterol, triglycerides) in serum and
mRNA expression of CD36, HO-1, TGF-β, IFN-γ, TNF-α, PPAR-γ and NADPH oxidase
components (p22phox, NOX-1 and Rac-1) was performed in aortic tissues by Real Time PCR. p21-
/- mice gained significantly (p < 0.01) more weight than wild type mice, triglycerides (p < 0.05) and
cholesterol levels (p < 0.01) were more pronounced in the sera of p21-/- compared to wild type
mice fed with high fat diet. High fat diet resulted in significantly decreased TGF-β (p < 0.02), HO-l
(p < 0.02) and increased CD36 (p < 0.03) mRNA expression in aortic tissues of p21-/- mice
compared to animal fed with regular diet. IFN-γ mRNA expression (235 ± 11 folds) increased
significantly in high fat diet fed p21-/- mice and a multifold modulation of PPAR-γ(136 ± 7), p22phox,
NOX-1 and Rac-1 (15–35-folds) mRNA in aortic tissues from p21-/- mice compared to the wild
type mice. Severity of atherosclerotic lesions was significantly higher in p21-/- compared to wild type
mice. The results demonstrate that the deficiency of p21 leads to altered expression of pro-
atherogenic genes, and severe atherosclerosis in mice fed with high fat diet. This opens the
possibility of p21 protein as a therapeutic tool to control progression of atherosclerosis.
Introduction
Atherosclerosis is one of the major causes of death in the
modern world. Despite large efforts, its pathogenesis
remains largely unclear. More recently, atherosclerosis is
considered to be a disease of inflammation [1-4]. The pre-
cise events leading to inflammation/immune activation
in atherosclerosis are not fully understood. Aberrant pro-
liferation of smooth muscle cells is one of the key factors
in the pathogenesis of atherosclerosis. Therefore, mole-
cules that control cellular proliferation play a significant
role in the understanding of underlying mechanisms of
the pathogenesis of atherosclerosis. Transforming growth
factor-beta (TGF-β) is one of the most potent inhibitor of
smooth muscle cell proliferation [5], its expression
decreases in atherosclerosis [6,7], highlighting its role in
the pathogenesis of atherosclerosis [8]. Besides, these
reported protective effects of TGF-β, its role in atheroscle-
rosis is controversial because studies have demonstrated a
causative role of TGF-β in the pathogenesis of atheroscle-
rosis is reported based on the studies, which demonstrate
that active TGF-β in smooth muscle cells promote lipid
accumulation via increased synthesis [9-11] and deposi-
tion of proteoglycan in intima, known to be associated
with increased atherosclerosis [12,13]. In another study,
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TGF-β expression was considered to be a determinant for
the extent to which developing atherosclerotic lesions are
stabilized by a collagen-rich fibrous cap and higher levels
of TGF-β in SMC of stable lesions compared to the unsta-
ble lesions were observed [14]. These studies suggest that
the role of TGF-β may be detrimental in atherosclerosis.
Studies have shown that TGF-β induces expression of cyc-
lin kinase inhibitor p21, which mediates its inhibitory
effects [15]. Overexpression of p21 has been shown to
reverse atherosclerosis in experimental models of athero-
sclerosis. [16]. In addition to inducing expression of pro-
tective molecules like p21, TGF-β also inhibits the
expression of CD36, a scavenger of LDL [17]. We have ear-
lier demonstrated 5 that the aberrant proliferation of
smooth muscles due to the deletion of TGF-β gene was
restored by p21. Therefore, it suggests that p21 play a sig-
nificant role in the control of aberrant proliferation of
smooth muscle cells, an essential event in the pathogene-
sis of atherosclerosis. Furthermore, the protective role of
heme oxygenase-1 (HO-1) in atherosclerosis is also attrib-
uted to its induction of p21 [18]. Similarly, other studies
have demonstrated that the positive effects of HO-1 are
associated with increased expression of p21 that promotes
the inhibition of smooth muscle cell proliferation and
provides protection against atherosclerosis [19-21]. Also,
atherosclerosis is considered to be due to a state of height-
ened oxidative stress [22] and p21 provides protection
from oxidative stress [23,24]. Therefore, these studies
were performed to understand the role of p21 on the
pathogenesis of atherosclerosis using p21-/- mice. The ani-
mals were fed either a high fat or regular diet. Aortic
expression of TGF-β, CD36, HO-1, IFN-γ, PPAR-γ and
NADOH oxidase components (p22phox, NOX-1 and Rac-
1) was studied and histopathology was quantified. The
results demonstrate that the modulation of p21 can assist
in dissecting the events leading to the initiation and devel-
opment of atherosclerosis.
Materials and methods
Mice and treatment
Mice (6 weeks old) lacking p21 (p21-/-) were bred from a
breeding pair generously provided by Dr. Philip Leder,
Howard Hughes Medical Institute, Boston. Strain
matched (FVB) wild type mice were purchased from
Taconic Labs. Wild-type (6 weeks old) and p21-/- mice (24
each) were fed initially with regular diet, which consisted
of <0.05% cholesterol, approximately 5% of animal fat
without casein or sodium cholate, and then were fed with
a standard atherogenic diet. The high-cholesterol diet
from Dyets Inc. Bethlehem, PA USA) were used. The high
cholesterol diet was continued for 21 weeks when a peak
of atherosclerosis is achieved. All studies were performed
with approved institutional IACUC protocols.
Lipid profile
Sera was separated and stored at -80°C until analysis.
Using specific kits from Wako Chemicals Richmond, VA,
USA, levels of total cholesterol and triglycerides were
quantified from sera samples obtained at study endpoint
(21 weeks of high cholesterol diet)..
Analysis of mRNA expression of pro-and anti-atherogenic 
intermediates in atherosclerosis
We performed real-time quantitative RT-PCR for IFN-γ,
PPAR-γ and NADPH oxidase components (p22phox,
NOX-1 and Rac-1) mRNA using a Bio-Rad iCycler system
(Bio-Rad, Hercules, CA). RNAs were isolated from cardiac
l tissues using a kit from Promega (Madison, USA) and
reverse-transcribed into cDNAs by using a cDNA synthesis
kit from invitrogen (Carlsbad CA). The amplification of
specific mRNA expression was achieved by polymerase
chain reaction (PCR) using specific primer sequences for
TGF-β; sense: 5'-GGGACTA TCCACCTGCAAGA-3'; anti-
sense: 5'-CACGTGCTGCTCCACTTTTA-3'; CD36; sense:
5'-AGATGCA GCCTCATTTCCAC-3'; antisense: 5'-GCCTT-
GGATGGAAGAACAAA-3';  HO-1; sense: 5'-TCCGAT-
GGGTCCTTACACTC-3'; antisense: 5'-
ATTGCCTGGATGTGCTTT TC-3' and β-actin; sense: 5'-
TGACGGGGTCACCC ACACTGTGAACATCTA-3'; anti-
sense, 5'-CTTGAAGCATTTGCGGTGGACGATGGAGGG-
3'; IFN-γ sense 5'-TCTGGAGGAACTG GCAAAAG-3', anti-
sense 5'-TTCAAGACTTCAAAGAGTC TGAGG-3'; p22phox
sense 5'-G CCATTGCCAGTGTGATCTA-3'; antisense: 5'-
AATGGGAGTCCACTGCTCAC-3';  NOX-1; sense: 5'-
GGCATCCCTTTACTCTG ACCT-3'; antisense: 5'-TGCT-
GCTCGAATATGAA TGG-3'; Rac-1; sense: 5'-GTA CATC-
CCCACCGTCTTTG-3'; antisense: 5'-CCCAGATTC
ACTGGTTTTC-3' and β-actin  sense: 5'-CCCAG-
CACAATGA AGATCAA-3' and antisense 5'-CG ATC-
CACACGGAGTACTTG-3. The primers were tested by
running a regular PCR for 40 cycles at 95°C for 20 s and
60°C for 1 minute, and followed separating in ethidium
bromide containing agarose gels. The real-time PCR was
performed using a SYBR supermix kit (Bio-RAD), and run-
ning for 40 cycles at 95°C for 20 s and 60°C for 1 minute.
The PCR efficiency was also examined by serially diluting
the template cDNA and the melting curve data was col-
lected to check the PCR specificity and proper negative
controls were included in each assay. The mRNA level for
each gene for each sample was normalized to β-actin
mRNA and quantified using a formula; 2 [(Ct/β-actin –
Ct/gene of interest)]. The results are expressed as fold dif-
ference in high fat diet fed compared to regular diet fed
p21-/- mice.
Histology and Morphometry
The differences among the high cholesterol fed wild-type
mice and p21-/- mice regarding atherogenesis was evalu-
ated quantitatively by microscopic examination theJournal of Biomedical Science 2009, 16:66 http://www.jbiomedsci.com/content/16/1/66
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atherosclerotic lesions. Serial cross-sections at least in trip-
licate were cut through the aortic coronary artery region,
beginning with the appearance of all three-valve cusps as
described by Daugherty and Whitman [25]. The sections
were stained with Hematoxylin-and-eosin and Oil Red O,
and counter-stained with hemalum. The quantification of
the atherosclerotic lesions was made by using an Olympus
microscope and by computer-aided morphometry soft-
ware Image J. The average lesion size for each mouse were
calculated and converted in to percent of total area
counted. Statistical analysis was performed by the use of
statistical software (GraphPad, San Diego).
Data analysis
Differences between groups were determined using two-
tailed unpaired T test with significance considered present
at a p value of less than 0.05. Statistical analysis was per-
formed using a software program from GraphPad Soft-
ware, Inc., San Diego, CA 92121 USA. The results are
expressed as Mean ± SEM.
Results
Weight gain
Wild-type mice gained weight (22 ± 1.2 g vs 35 ± 1.5 g, p
< 0.01) when fed with high fat diet, however weight gain
in and p21-/- was significantly higher (24 ± 1 vs 46.4 ± 2.3
g, p < 0.001) when fed with high fat diet. Interestingly,
weight gain in p21-/- mice was significantly higher (p <
0.01) compared to wild-type mice also fed with high fat
diet (Figure 1A).
Triglycerides and Cholesterol Levels
These results demonstrate that p21-/- mice compared to
their wild type counterparts were more prone to the effects
of high fat diet. Circulating levels of cholesterol and trig-
lycerides levels in sera of mice from each group were
quantified (Figure 1B). Triglycerides levels increased in
wild-type mice fed with high fat diet compared to mice fed
with regular diet (11-± 3 vs 21 ± 2 mg/dl). However, the
increase of triglycerides levels was more pronounced in
sera of p21-/- mice fed with high fat diet compared to reg-
ular diet (19 ± 2.5 vs 41 ± 6 mg/dl p < 0.001). A significant
(p < 0.05) increase in triglycerides levels was observed
when we compared levels of wild-type and p21-/- mice.
Similar results were obtained with quantification of cho-
lesterol levels. The circulating levels of cholesterol
increased in wild-type mice fed with high fat diet com-
pared to mice fed with regular diet (31 ± 4 vs 60 ± 4 mg/
dl p < 0.05). However, the increase of cholesterol levels
was more pronounced in sera of p21-/- mice fed with high
fat diet compared to regular diet (42 ± 6 vs 88 ± 11 mg/dl
p < 0.001). A significant (p < 0.05) increase in circulating
levels of cholesterol was observed when levels in sera of
wild-type and p21-/- mice fed with high fat diet were com-
pared.
Effect of high fat diet on mRNA expression of anti-
atherogenic (TGF-β, HO-1) and pro-atherogenic (CD36) in 
p21-/- mice
TGF-β mRNA expression
The expression of TGF-β mRNA in aortic tissues of mice
fed with high fat diet was compared in mice fed with high
fat and regular diet. Total RNA from aortic tissues was
reverse transcribed to cDNA and amplified for TGF-β
mRNA by PCR. In wild-type and p21-/- mice, TGF-β mRNA
expression decreased though in wild-type mice the
decrease was not significant (Figure 2A). In p21-/- mice a
highly significant (p < 0.02) decrease was observed. We
also have data on TGF-β mRNA expression in aortic tis-
sues from p21-/- mice fed with regular or high fat diet. A
highly significant (p < 0.01) decrease in TGF-β mRNA was
observed in high fat diet fed mice compared to mice fed
with regular diet [Relative TGF-β mRNA expression (M ±
SEM) n = 4, .5 ± 0.4 vs 3.6 ± 0.3).
CD36 mRNA expression
Based on its role in the pathogenesis of atherosclerosis, it
was hypothesized that the expression of CD36 mRNA in
aortic tissues of mice fed with high fat diet will be more
than mice fed with regular diet. In wild-type and p21-/-
mice, CD36 mRNA expression increased but in p21-/- mice
a highly significant (p < 0.03) increase was observed (Fig-
ure 2B) compared to wild type mice. The expression of
CD36 mRNA was significantly more (p < 0.05) in p21-/-
mice fed with high fat diet compared to wild-type mice
also fed with high fat diet.
HO-1 mRNA expression
HO-1 has been shown to be protective in atherosclerosis,
therefore, mRNA expression was studied in p21-/- mice fed
with high fat diet and compared to wild-type mice fed
with similar diet. Total RNA from aortic tissues was
reverse transcribed to cDNA and amplified for HO-1
mRNA by PCR. In both wild-type and p21-/- mice HO-1
mRNA expression decreased but in p21-/- mice a highly
significant (p < 0.002) decrease was observed (Figure 2C).
Effect of high fat diet on mRNA expression of IFN-γ, PPAR-
γ and NADPH oxidase components (p22phox, NOX-1 and 
Rac-1) in p21-/- mice
IFN-γ mRNA expression was studied by Real time PCR
analysis. IFN-γ mRNA increased in p21-/- mice fed with
high fat diet compared to those fed with regular diet.
These results amplification peaks in a real time PCR reac-
tion (Figure 3A) show that IFN-γ mRNA was detectable at
a very low levels in regular diet fed group compared to sig-
nificantly higher (236 ± 11 fold) in p21-/- mice compared
to (12 ± 1.6 fold) in wild type mice fed with high fat diet
(Figure 3B). To understand the role of peroxisome prolif-
erator-activated receptors (PPARs) in the development of
atherosclerosis, the expression patterns of mRNA ofJournal of Biomedical Science 2009, 16:66 http://www.jbiomedsci.com/content/16/1/66
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Body weight (BW), plasma cholesterol, and plasma triglyceride levels in p21-/- and wild type control mice Figure 1
Body weight (BW), plasma cholesterol, and plasma triglyceride levels in p21-/- and wild type control mice. A: 
Differential effect of high fat diet on weight gain in wild type mice (n = 8) and p21-/- (n = 8) mice is shown. Values are means ± 
SEM, Weight gain in p21-/- mice fed with high fat diet is compared to p21-/- mice fed with regular diet and wild type mice fed 
with high fat diet. B: Differential effect on the effect of high fat diet on plasma levels of cholesterol (open bars) and triglycerides 
(closed bars) in p21-/- and wild type mice fed with high fat and regular diet is shown.
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Atherogenesis related gene expression in p21-/- and wild type control mice Figure 2
Atherogenesis related gene expression in p21-/- and wild type control mice. Intra-aortic analysis of mRNA expres-
sion for anti-atherogenic TGF-β (A), HO-1 (B) and pro-atherogenic gene CD36 (C) is shown. Values presented are means ± 
SEM in wild type (n = 8) and p21-/- mice (n = 8) fed with regular and high fat diet.
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Quantitative mRNA expression of IFN-γ, PPAR-γ and NADPH oxidase components (p22phox, NOX-1 and Rac-1) in aortic tis- sues from p21-/- mice Figure 3
Quantitative mRNA expression of IFN-γ, PPAR-γ and NADPH oxidase components (p22phox, NOX-1 and Rac-
1) in aortic tissues from p21-/- mice. Amplification curves for IFN-g in RNA isolated from aorta from mice fed with high fat 
diet (HFD) and regular diet (RGD) are shown. Significantly higher Relative fold expression of IFN-γ (B), PPAR-γ (B) mRNA is 
shown in Wild type (open bars) and p21-/- mice (closed bars). The values are means ± SEM of fold increase in high fat diet com-
pared to the results obtained from mice fed with regular diet.
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PPAR-gamma in aortic tissues from mice was investigated.
Higher PPAR-γ mRNA was detected in aortas from p21-/-
mice (136 ± 7.3-folds) compared to wild type mice (15 ±
2.7) fed with either high fat diet (Figure 3C). PPAR-γ is
likely to be an important regulator of monocyte/macro-
phage function with relevance for human atherosclerotic
disease.
The results of mRNA expression of NADPH oxidase com-
ponents is shown in Figure 4, the expression of p22phox,
NOX-1 and Rac-1 increased 29 ± 1.6, 32 ± 2.1 and 15.6 ±
1.2 folds, respectively in high fat diet fed compared to reg-
ular diet fed p21-/- mice. Significantly lower values were
observed in wild type mice (data not shown).
Histopathological Analysis
The histological analysis of cross-sections cut through the
aortic coronary artery region are shown Figure 5A. The
results shows marked differences in p21-/- mice fed with
high fat diet (d) either compared to p21-/- mice fed with
regular diet (c) or wild type mice fed with high fat diet (a),
a low power view of a coronary artery showing narrowing
of the lumen by atheromatous plaque and scar areas
(black arrows) are shown. The score of lesions are
expressed as the percent lesions, quantified in aortas from
wild type and p21-/- mice fed with either regular diet or
high fat diet and expressed as mean ± SEM. Percent area
with aortic lesions was higher (4 ± 0.4% vs 10.2 ± 0.3%, p
< 0.01) in wild type fed with high fat diet compared to reg-
ular diet. However, the extent of severity of atherosclerotic
lesions was significantly more (8.4 ± 0.6% vs 30.9 ± 0.8%,
p < 0.0001) in p21-/- mice (Figure 5B).
Discussion
The results from this study demonstrate that p21-/- mice
exhibited tendency towards increased atherosclerosis
when fed with high fat diet. This included significantly
more gain in weight than mice fed with regular diet. Sim-
ilarly, p21-/- mice fed with high fact diet showed signifi-
cantly increased circulating levels of cholesterol and
triglyceride compared to p21-/- mice fed with regular diet
and wild type mice fed with high fat diet. The results from
gene expression analysis of pro- and anti-atherosclerotic
molecules such as TGF-β, HO-1 and CD36 suggests that
high fat diet differentially modulate these genes in p21-/-
and wild type mice in favor of atherogenesis. The aortic
tissue mRNA of TGF-β decreased minimally in wild type
mice fed with high fat diet but the decrease was signifi-
cantly more in p21-/- mice fed with high fat diet compared
to same mice when fed with regular diet. In sharp contrast,
intra aortic CD36 mRNA was significantly higher in p21-/
- mice fed with high fat diet compared to same mice fed
with regular diet and wild type mice fed with high fat diet.
These studies suggest such a sequential relationship
between TGF-β and CD36 in atherosclerosis. CD36 was
recognized more than two decades ago as a membrane
glycoprotein, initially considered to be a receptor for
thrombospondin-1 (TSP-1). However it is now realized to
be a multi ligand scavenger because besides TSP-1, its lig-
ands are long-chain fatty acids, modified LDL, retinal
photoreceptor outer segments, malarial parasite, malaria-
parasitized erythrocytes, sickle erythrocytes, anionic phos-
pholipids, apoptotic cells, and collagens I and IV [26,27].
Among the various activities of CD36 are cell attachment,
motility, proliferation, and regulation of protease activity,
angiogenesis and above all TGF-β activation. Therefore,
CD36 is also termed as multi-ligand scavenger receptor
and one of the important pathologic functions of scaven-
ger receptors, related to foam cell formation and the
pathogenesis of atherosclerosis, is recognition and inter-
nalization of oxidatively modified LDL. Furthermore, the
most compelling data supporting the role for CD36 in
foam cell formation and atherosclerosis are from studies
with CD36-knockout mice. Macrophages isolated from
these animals were found to be defective in uptake of
oxLDL and foam cell formation. Also, breeding the CD36
deficient mice with proatherogenic ApoE-/- mice resulted
in significant protection of animals from lesion develop-
ment. Animals fed a Western diet showed a >70% reduc-
tion in aortic lesion size and distribution [28]. TGF-β has
been shown to inhibit expression of CD36 [21,29]. A defi-
ciency in TGF-β, which also results in deficiency of p21 5
could result in increased expression of CD36 leading to
Quantitative mRNA expression of NADPH oxidase compo- nents (p22phox, NOX-1 and Rac-1) in aortic tissues from p21- /- mice Figure 4
Quantitative mRNA expression of NADPH oxidase 
components (p22phox, NOX-1 and Rac-1) in aortic tis-
sues from p21-/- mice. The results of mRNA expression of 
NADPH oxidase components; p22phox, NOX-1 and Rac-1 
are shown as fold increase in high fat diet (HFD) treated p21-
/- mice (n = 8) using results from regular diet (n = 8) treated 
mice as controls (RGD).
0
5
10
15
20
25
30
35
40
45
p22 NOX-1 Rac-1
F
o
l
d
 
i
n
c
r
e
a
s
e
 
i
n
 
H
F
D
 
o
f
 
R
G
D
 
g
r
o
u
p
p22phoxJournal of Biomedical Science 2009, 16:66 http://www.jbiomedsci.com/content/16/1/66
Page 8 of 12
(page number not for citation purposes)
Histology and morophometry of atherosclerotic lesions Figure 5
Histology and morophometry of atherosclerotic lesions. Photomicrographs of light microscopy of representative sec-
tions of the coronary artery tissues from p21-/- and wild type mice. Magnification is ×20 for all tissues. Haematoxylin and eosin 
staining of in the coronary artery issues of wild type mice fed with regular diet (a), high fat diet (b); p21-/- mice fed with regular 
diet (c) and high fat diet (d) is shown. Black arrows indicate areas with scar. The graph (B) shows the mean lesion area (val-
ues are Mean ± SEM) per mouse. *p < 0.01, high fat diet (HFD) vs regular diet (RGD), wild type mice and **p < 0.0001, high fat 
diet vs regular diet in p21-/- mice.
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severe atherosclerosis. The results from these experiments
demonstrate such a reciprocal profile of CD36 and TGF-β
mRNA, suggesting that high fat diet in p21-/- mice tilted
the balance towards atherogenesis.
The analysis of HO-1 mRNA indicate that similar to TGF-
β mRNA expression, its expression decreased significantly
in p21-/- mice fed with high fat diet compared to regular
diet. The decrease in wild type mice also fed with high fat
diet was minimal, suggesting the direct effect of p21 defi-
ciency on HO-1 mRNA expression in aortic tissues of mice
fed with high fat diet. HO-1 is an inducible form of heme
oxygenase and possesses a variety of adaptive responses
against oxidative stress. A number of factors, which
include ischemia/reperfusion, hypertension, proinflam-
matory cytokines, or oxidized LDL, induce expression of
HO-1 [30]. The HO reaction involves degradation of
heme leading to its conversion to into biliverdin, carbon
monoxide, and free iron [31,32]. These events are consid-
ered to provide protective roles against stresses in the vas-
cular wall caused by a variety of pathological changes.
Oxidative alteration of lipoproteins in vascular wall,
which supposedly leads to the initiation and development
of atherosclerosis mediate the relationship of HO-1 with
atherosclerosis. HO-1 modulation in rabbits [33] and
mice [34,35] demonstrated anti-atherogenic effects of
HO-1.
Our findings that the aortic mRNA expression of HO-1 in
p21-/- mice decreases when fed with high fat diet and
develop atherosclerosis are of significance, since with ref-
erence to atherosclerosis there are functional similarities
between p21 and HO-1. Both these molecules promote
cell arrest, one of the key step in preventing smooth mus-
cle cell proliferation and atherosclerosis. Furthermore,
p21 seems to be of more significance, since growth inhi-
bition and cell-cycle arrest in HO-1 expressing cells was
shown to be associated with induction of p21 [21]. Inter-
estingly, HO-1 deficient cells lack or have reduced p21
expression, in the present study, opposite seems to be
true, in p21-/-  mice, HO-1 expression significantly
decreased when fed with high fat diet.
Atherosclerosis is a disease of inflammation. [1-4], in this
study; we demonstrate that p21-/- mice when fed with high
fat diet developed significantly severe atherosclerosis
compared to same mice fed with regular diet or wild type
mice fed with high fat diet. To understand if inflammation
was responsible in these mice, IFN-γ mRNA was analyzed
in aortic tissues. The results demonstrate that high fat diet
in p21-/- mice resulted in significantly increased IFN-γ
mRNA compared to the same mice fed with regular diet or
wild type mice fed with high fat diet. These results suggest
that p21 deficiency results in an increased inflammatory
response to a high fat diet. Exogenous IFN-γ has been
shown to enhance high fat diet induced atherogenesis in
ApoE-/- mice [36,37] and IFN-γ and TNF-α knockout mice
did not develop severe atherosclerosis when fed with a
diet with high cholesterol [38,39]. There is a large body of
evidence suggesting a potent role of inflammation in
atherosclerosis. T lymphocytes isolated from atheroscle-
rotic plaques were found to have increased expression of
IFN-γ and HLA class II molecules indicating the state of T
cell activation [40-42]. Besides IFN-γ, PPAR-γ mRNA in
the aortic tissues of p21-/- mice increased significantly in
response to high fat diet compared to regular diet. Though
the precise role of PPAR-γ in atherosclerosis is not clear, it
has been linked to the development of inflammation and
studies [43] have shown its increased expression in mac-
rophage foam cells of human atherosclerotic lesions and
endothelial cells of human carotid arteries.
Oxidative stress has been shown to be a key factor in the
pathogenesis of atherosclerosis. However, there is a lack
of sufficient knowledge delineating the precise molecular
events and the mediators involved in this process. The
gene expression for NADPH oxidase components
(p22phox, NOX-1 and Rac-1) was studied in aortic tissues
from p21-/- mice fed with high fat diet and compared with
same mice fed with regular diet. It is conceivable that the
increased activity of NADPH oxidase components
reflected by multifold increased mRNA expression con-
tributed to severe atherosclerosis in these mice. Increased
expression of p22phox has been associated with increased
vascular smooth muscle cell proliferation and increased
expression of gp91phox and p22phox mRNA was associated
with the severity of atherosclerosis [22]. The results from
this study suggest that in the absence of p21, its protective
effects on oxidative stress [23,24] are lost that result in
increased NADPH oxidase activity i.e. oxidative stress and
severe atherosclerosis in p21-/- mice fed with high fat diet
compared to the regular diet.
These studies accumulatively provide direct evidence for a
potential protective role of p21 in vivo for vascular disor-
ders involving proliferative disorder specifically athero-
sclerosis. This may be due to aberrant smooth muscle cell
proliferation in these mice. p21 has been shown to inhibit
both the migration and proliferation of smooth muscle
cells [44] and adenovirus mediated p21 gene expression
in rat vascular smooth muscle cells inhibited proliferation
[45]. Also in a porcine balloon arterial model, adenovirus-
mediated transfer of the p21 gene resulted in 35% reduc-
tion of in vivo cell proliferation and intimal thickening
[46]. The inhibition of p27, another potent cyclin inhibi-
tor, blocked Ang II induced hypertrophy and promoted
hyperplasia indicating a role of cell cycle control in the
pathogenesis of atherosclerosis and other vascular disor-
ders [47]. These studies indicate a role of cell cycle control
and most significantly of p21 in the arrest of cellularJournal of Biomedical Science 2009, 16:66 http://www.jbiomedsci.com/content/16/1/66
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growth in atherosclerosis. Our own studies [48,49] have
demonstrated that p21 overexpression reduces mitogen-
induced lymphocyte proliferation and inflammation, one
of the key mediators in the pathogenesis of atherosclero-
sis. A number of studies have demonstrated the role of
p21 as a protective agent in atherosclerosis. Inhibition of
Akt pathway resulted in decreased SMC proliferation and
decrease in p21 expression abolished this inhibition [50].
These results demonstrated that p21 may be an integral
part of the events leading to the inhibition of SMC prolif-
eration. During progesterone-induced inhibition of rat
aortic smooth muscle cell proliferation the expression of
CDK2 and CDK4 and of p21 and p27 increased. NSAIDs
aspirin, sodium salicylate, diclofenac, ibuprofen,
indomethacin and sulindac induce a dose-dependent
inhibition of proliferation in rat A10 VSMCs and the
expression of p21 and p27 were increased [51] and trani-
last-mediated inhibition of SMC was due to the increased
expression of p21 [52]. Tranilast efficiently inhibited the
smooth muscle cell proliferation but not those isolated
from p21-/- mice. The in vivo experiments also confirmed
the role of p21 in limiting SMC proliferation, since the
administration of tranilast significantly reduced the
neointimal VSMC hyperplasia in wild-type mice but not
in p21-/- mice. IL-β induced SMC proliferation resulted in
decreased p21 expression [53] Statins have been shown to
have multiple activities in vascular disorders including
atherosclerosis. The inhibition of the mitogen-induced
proliferation of microvascular endothelial cell by Cerivas-
tatin, an inhibitor of 3-hydroxy-3-methylglutaryl coen-
zyme A reductase, which inhibits the biosynthesis of
cholesterol and its precursors: farnesyl pyrophosphate
and geranylgeranyl pyrophosphate (GGPP) was associ-
ated with the increase of p21 expression. Most interest-
ingly adenoviral mediated overexpression of p21 in
hypercholesterolemic ApoE-/- mice and resulted in a sig-
nificant reduction of restenosis in these mice [54]. An
inhibition of TSP-1 by a neutralizing A4.1 anti-TSP1 anti-
body prevented proliferation of serum-stimulated VSMCs.
and was followed by a significant induction of p21 expres-
sion in A4.1-treated VSMCs [55]. Therefore, the results
showed that p21 played an important role in TSP1-medi-
ated control of cellular proliferation.
In summary these studies suggest that p21 is protective in
atherosclerosis, though mechanism of its effect may not
be completely clear. Based on our published studies on
the anti-inflammatory effects of p21 [56] and the
increased inflammation in p21-/- mice, it can be specu-
lated that p21 deficiency in the presence of high fat diet
resulted in the development of atherosclerosis. In a
number of other studies [57], efficacy of overexpression of
p21 as an anti-inflammatory agent has been documented
that includes experimental models of arthritis and sys-
temic lupus erythmatosus (SLE). There is only one study
with opposite effects than the data presented in this study.
The authors [58] showed that p21 is proatherogenic mol-
ecule since inactivation of p21 protected against athero-
sclerosis by stimulating apoptosis, enhancing
inflammation etc. However, there is no proven direct rela-
tionship between either facilitation of inflammation or
phagocytic action of macrophages. Studies have strongly
suggested that vascular proliferation and inflammation
are linked [59] and coupled with the notion that cell cycle
control and inflammation are also connected, makes
extremely impossible to think that the deficiency of p21
could result in aggravated atherosclerosis. Initial studies
have shown that an initial insult to endothelium results in
release of growth factor and cytokines that stimulate the
proliferation of smooth muscle cells. Interestingly, prolif-
eration of smooth muscle cells remains one of the key
events in the pathophysiology of atherosclerosis. The
strongest evidence is provided by the studies demonstrat-
ing that the proliferation of SMC is limited as a conse-
quence to the inhibition of cell cycle progression by
modulation of p21 or antisense oligonucleotides (ODNs)
against c-myc [5]. These studies clearly and directly dem-
onstrate the protective but not the pro-atherogenic prop-
erties of p21.
Therefore, based on a large number of supportive studies
suggesting multiple positive effects including hematopoi-
esis, carcinogenesis, nephrotoxicity and inflammation, it
is highly unlikely that p21 deficiency will lead to aggra-
vated atherosclerosis. In contrary, p21 deficiency, as
observed in this study, will result in increased inflamma-
tion and more severe atherosclerosis. Besides, a number of
studies, which have demonstrated that modulation of p21
alter cellular proliferation and inflammation, our recent
studies have uniquely demonstrated that recombinant
p21 protein localizes into nucleus of lymphocytes, inhibit
cellular proliferation and inflammation [56]. Therefore,
based on the anti-inflammatory and anti-proliferative
effects of p21, we speculate a therapeutic role of p21 in
limiting the development and progression of atheroscle-
rosis.
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